tbuckley/cabot-search huggingface dataset:
Abstract P281: All-cause and Cardiovascular Mortality in Men With High Levels of Physical Activity and Coronary Artery Calcification
Authors: Laura F Defina, Nina B Radford, David Leonard, Stephen W Farrell, Andjelka Pavlovic, Benjamin L Willis, Carolyn E Barlow, Benjamin D Levine
Journal: Circulation (2018)

Introduction: Recent studies have suggested that extreme levels of physical activity (endurance athletes) are associated with subclinical atherosclerosis as well as increased mortality. The safety of continuing high levels of physical activity is uncertain once coronary artery calcification (CAC) is discovered. Hypothesis: We hypothesized that men performing &amp;ge3000 MET·minutes/week of physical activity would have greater all-cause and cardiovascular (CV) mortality compared to those with &amp;lt1500 or 1500-&amp;lt3000 MET·minutes/week of physical activity and that mortality risk would be greater in those with CAC&amp;ge100 compared to &amp;lt100 Agatston units. Methods: The cohort studied included 16,109 men without prevalent CV disease who reported physical activity levels and underwent EBT or MDCT scan. Physical activity was categorized into &amp;ge3000 (n=1,266), 1500-3000 (n=3,027), and &amp;lt1500 (n=11,816) MET·minutes/week. CAC scanning included EBT scans (1997-2007) or MDCT scans (2007-2013), and CAC score was categorized into &amp;ge100 (n=3,547) and &amp;lt100 (n=12,562) Agatston units. We fit separate proportional hazards regression models to follow-up times for all-cause and CV mortality. The models included all combinations of CAC and physical activity categories and were adjusted for baseline age, smoking, BMI, cholesterol, HDLc, and systolic blood pressure. Results: The average age of participants at baseline was 51.3±8.3 years. Men with the highest activity level had a lower BMI and higher HDLc. After an average follow-up of 8.9 years, there were 329 all-cause and 60 CV deaths, including 174 all-cause and 38 CV deaths in those with CAC&amp;ge100. The sample had 80% power to detect all-cause mortality hazard ratios &amp;ge 1.9 and 1.8 for physical activity &amp;ge3000 versus &amp;lt1500 in those with CAC&amp;lt100 and &amp;ge100, respectively. The corresponding minimum detectable CV mortality hazard ratios were 3.5 and 2.8. Comparing physical activity &amp;ge3000 to &amp;lt1500 in those with CAC&amp;ge100, the hazard ratios (95% CI) were 0.9 (0.5, 1.5) for all-cause mortality and 0.9 (0.3, 3.1) for CV mortality. Hazard ratios were similar when comparing physical activity &amp;ge3000 to 1500-&amp;lt3000 in those with CAC &amp;ge100. Finally, when comparing physical activity categories, there was no evidence that hazard ratios varied by CAC category, p&amp;gt0.7. Conclusions: This sample offers no evidence that levels of activity &amp;ge3000 MET·minutes/week are associated with increased all-cause or CV mortality compared to those with &amp;lt1500 or 1500- &amp;lt3000 MET·minutes/week, regardless of CAC level.
Book Review Therapeutic Uses of Infra-Red Rays . By W. Annandale Troup, M.C., M.D., Ch.B., London, England. With foreword by Sir Wm. Willcox, K.C.I.E., C.B., C.M.G., M.D. 1 Volume, 57 pages, published 1930, price $1.50.
Journal: New England Journal of Medicine (1931)
JAMA reference directories
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE GERM-THEORY OF DISEASE AND ANTISEPTIC TREATMENT. BY W.T. ECKLEY, M.D....
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lorlatinib Outperforms Crizotinib in NSCLC
Journal: Cancer Discovery (2020)

The CROWN study suggests that lorlatinib is effective in patients newly diagnosed with advanced ALK-positive non-small cell lung cancer. In the phase III trial, patients treated with lorlatinib were twice as likely to be alive without disease progression after 1 year than those who received crizotinib-with slower progression of brain metastases.
Changes in the expression of a junctional protein are associated with mutational status of BRAF and survival in melanoma
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Scatolini et al. Br J Dermatol 2022; 186:117–128. Melanoma is a serious form of skin cancer that arises when pigment cells in the skin (melanocytes) become malignant (cancerous). During their lifetime melanoma develops in about 1 in 40 people in the UK. Melanoma can spread to other parts of the body (i.e. ‘metastasize’), and metastatic melanoma is one of the deadliest cancers. Several mutations (faults in genetic code) have been found in metastatic melanoma including the BRAF mutation. The development of a type of treatment using inhibitors of mutated BRAF have signalled a positive step in the fight against melanoma, with encouraging response rates. However, due to the development of resistance to such therapies, the search for additional combination treatments and new biomarkers to help predict which patients will respond to different treatments remains a challenge. Building on their previous research, the authors of this study (from Italy, Japan and the UK) focused on gaining a better understanding of melanoma biology, in order to improve treatment options and predict patient outcomes (their prognosis). It was previously known that a gap junction protein called connexin 31·1 (or GJB5) played a role in lung cancer but the authors of this current study have identified a link between metastases (i.e. where the cancer has spread), BRAF mutation and low GJB5 expression in melanoma. This study highlights the importance of monitoring this gap junction protein, and the findings suggest that GJB5 can be used as a prognostic (outcome) marker to predict melanoma progression. In addition, the authors suggest that with future research GJB5 may be a possible new treatment target that could be used in combination with current therapies in melanoma. Linked Article: Scatolini et al. Br J Dermatol 2022; 186:117–128.
Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma
Authors: Dai Maruyama, Kensei Tobinai, Kiyoshi Ando, Ken Ohmachi, Michinori Ogura, Toshiki Uchida, Tadashi Nakanishi, Masayuki Namiki
Journal: Blood (2015)
Lymphadenopathies in Homosexual Men
Authors: Harry L. loachim
Journal: JAMA (1983)

Generalized, persistent lymphadenopathies were observed in homosexual men and considered a possible prodrome of acquired immune deficiency syndrome (AIDS). To evaluate these lymphadenopathies, 25 lymph node biopsy specimens from homosexual men with lymphadenopathy (18), lymphadenopathy associated with AIDS (five), and lymphadenopathy associated with non-Hodgkin's lymphoma (two) were reviewed and correlated with the clinical symptoms. In the absence of opportunistic infections, the lymph node lesions were essentially uniform and represented acute inflammatory processes resembling those commonly seen in viral lymphadenitides. This suggests that a lymphotropic agent, probably a virus, causes AIDS as a result of its destructive effects on certain populations of lymphoid cells. (<i>JAMA</i>1983;250:1306-1309)
Contents
Authors: Ella Leung, Allister Gibbons, Douglas Koch, Edoardo Villani, Luca Marelli, Francesco Bonsignore, Stefano Lucentini, Saverio Luccarelli, Matteo Sacchi, Massimiliano Serafino, Paolo Nucci, Taher Eleiwa, Amr Elsawy, Mohamed Tolba, William Feuer, Sonia Yoo, Mohamed Shousha, Vahid Mohammadzadeh, Alessandro Rabiolo, Qiang Fu, Esteban Morales, Anne Coleman, Simon Law, Joseph Caprioli, Kouros Nouri-Mahdavi, Ayub Qassim, Emmanuelle Souzeau, Owen Siggs, Mark Hassall, Xikun Han, Helen Griffiths, N Frost, Neeru Vallabh, James Kirwan, Geeta Frcophth, Angela Menon, Anna Cree, Ashish Galanopoulos, Paul Healey, Stuart Graham, John Landers, Robert Casson, Puya Gharahkhani, Colin Willoughby, Alex Hewitt, Andrew Lotery, Stuart Macgregor, Jamie Craig, Jessica Cooke Bailey, Jason Yam, Edin Fen, Fen Li, Xiujuan Zhang, Shu Tang, Benjamin Yip, Ka Kam, Simon Ko, Alvin Young, Clement Tham, Jia Li, Chi Pang, Evan Chen, Grayson Armstrong, Jacob Cox, M Phil, David Wu, Donald Hoover, Lucian Priore, Ravi Parikh, Andrew Bindman, Ling Chen, Jeffrey Messinger, Kenneth Sloan, Thomas Swain, Yoshimi Sugiura, Lawrence Yannuzzi, Christine Curcio, K Freund, Adeleh Yarmohammadi, Sally Baxter, Lilangi Ediriwickrema, Elliot Williams, Leslie Kobayashi, Catherine Liu, Bobby Korn, Don Kikkawa, Mumta Kanda, Victoria Nowak, Frcophth Reply, Damien Goldberg
Journal: Ophthalmology (2020)
GORGAS A MEMBER OF THE ISTHMIAN CANAL COMMISSION.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response to Comment on Parente et al. The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes. Diabetes Care 2021;44:1706–1713
Authors: Erika B. Parente, Emma H. Dahlström, Valma Harjutsalo, Jussi Inkeri, Stefan Mutter, Carol Forsblom, Niina Sandholm, Daniel Gordin, Per-Henrik Groop
Journal: Diabetes Care (2021)
“The beginning is the most important part of the work”
Authors: None The Lancet Microbe
Journal: The Lancet Microbe (2020)

In our very first Editorial, we outlined several aspirations, the first of which was to set ourselves apart from other journals in the clinical microbiology sphere by catering to work that furthered the understanding of microbes and other pathogens at all scales. The idea was to publish studies that contribute to health through a direct understanding of the pathogen and how the pathogen affects the host at a physiological level, but also how the pathogen impacts populations. And from these insights gain a clearer understanding of the role the pathogen plays in disease, of which it is only one factor.
Commentary
Authors: Klaus Mönkemüller
Journal: Endoscopy (2020)

Self-expanding metal stents (SEMSs) are useful to palliate malignant and benign gastrointestinal strictures and to bridge the gastrointestinal lumen in cases of leaks and fistulas. Occasionally, the stent axis may not align itself with the luminal gastrointestinal axis resulting in additional problems such as recurrent obstruction. As shown in this E-Video by Mangiavilliano et al., this problem can be solved by clipping on the proximal part of the SEMS located on the lesser curvature of the stomach. The authors clearly show that by approximating the mesh with the clip, the length of the SEMS is shortened in this location appropriately curving it and adapting the SEMS to the axis of the stomach lumen.
Swim Bladder as a Novel Biomaterial for Cardiovascular Materials with Anti‐Calcification Properties
Authors: Jing Liu, Binhan Li, Huimin Jing, Yongjian Wu, Deling Kong*, Xigang Leng*, Zhihong Wang*
Journal: Advanced Healthcare Materials (2022)

Adv. Healthcare Mater. 2020, 9, 1901154 https://doi.org/10.1002/adhm.201901154 In the original version of this article, Figure 1d-3 was incorrect due to a mix-up in uploading the images. This was not noticed at the time of submission and publication. The correct Figure 1 is shown below. These changes do not affect the overall conclusions of this study. The authors apologize for any inconvenience caused.
Effect of adding immunotherapy to standard of care on survival in patients with esophageal cancer: Analysis of NCDB database.
Authors: SABER Ali AMIN, Chi Lin
Journal: Journal of Clinical Oncology (2022)

325 Background: Combined immuno-chemotherapy has been shown to be more effective than chemotherapy alone in advanced esophageal cancer. However, the association of immunotherapy and overall survival (OS) of patients with esophageal cancer, regardless of stage and combined therapy, is unknown. The objective is to explore the association of immunotherapy with OS in patients with all stage esophageal adenocarcinoma or squamous cell carcinoma who received any treatment. Subset analysis was conducted on OS for patients who received chemoradiation with and without immunotherapy. Methods: This study included 85,900 adult patients in the National Cancer Database diagnosed between 2004 and 2017 with stage I-IV esophageal adenocarcinoma or squamous cell carcinoma. The association of immunotherapy with OS was assessed with Cox proportional hazards regression, adjusted for age at diagnosis, race, sex, stage, histology, Charlson score, education, income, insurance, hospital type, place of living, region, distance to facility, year of diagnosis and treatment modality. Results: Of 85,900 patients, 69,264 (81%) were men, 85,159 (88%) were White and 7,875 (9%) were Black. The median (range) age at diagnosis was 64 (18-90) years. Overall, 1990 (2.3%) received immunotherapy. Immunotherapy did not improve median OS in stage I-II (31 vs 27M, p &gt;.05) but improved median OS in stage III (from 18 to 30 M, p &lt;.0001) and IV (from 8 to 14 M p &lt;.0001). In the multivariable COX analysis, patients who received immunotherapy had significantly improved OS compared with no immunotherapy (HR 0.756; 95% CI 0.713-0.801; P =.001). Treatment with CRT without surgery plus immunotherapy was associated with significantly improved OS compared with CRT alone (HR 0.817; 95% CI 0.745-0.896; P =.001). Interestingly, addition of immunotherapy to CRT with surgery did not improve OS compared with CRT and surgery. After stratified by stage, immunotherapy was found to be associated with improved OS only in stage IV patients either in all patients (HR 0.685; 95% CI 0.641-0.731, p &lt; 0.001) or in patients who received CRT without surgery (HR 0.758; 95% CI 0.682-0.841). Conclusions: In this study, the addition of immunotherapy to standard of care, especially chemoradiation without surgery was associated with improved OS compared with standard of care (or chemoradiation) alone in patients with advanced stage esophageal cancer.
Hydrocephalus in the adult
Authors: P. A. Hogan
Journal: JAMA (1966)

Hydrocephalus in the adult may present symptoms of chronic headache, gait disturbance, dementia, or any combination of these symptoms. All known causes of hydrocephalus are represented in cases of adult onset and show the same clinical syndromes. Clinical features, cerebrospinal fluid examination, and electroencephalogram are not reliable means of differentiating hydrocephalus in adults from other conditions presenting similar symptoms. Pneumoencephalography shows a characteristic picture of generalized ventricular enlargement with air in the basilar cisterns which fails to pass over the cerebral convexities. Ventriculoatrial shunt usually completely reverses the neurological symptoms even when these have been present for many years. Four cases of hydrocephalus in adults are presented which illustrate various manifestations of hydrocephalus. Three patients showed remarkable improvement from long periods of neurological disability following ventricular cerebrospinal fluid shunt.
Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in <i>BRAF<sup>V600E</sup></i> CRC murine models.
Authors: Melanie Nicole Woods, Vincenzo De Falco, Claudia Prisco, Giulia Martini, Luigi Pio Guerrera, Valentina Belli, Teresa Troiani, Van K. Morris, John Paul Y.C. Shen, Hey Min Lee, Oscar Villarreal, Alexey Sorokin, Preeti Kanikarla Marie, Fortunato Ciardiello, Scott Kopetz, Stefania Napolitano
Journal: Journal of Clinical Oncology (2022)

145 Background: Based on promising results from latest trials, a crucial point is to evaluate whether encorafenib (E) plus cetuximab (C), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care in previously untreated BRAF V600E mutant mCRC. Considering the high number of BRAF V600E mutant mCRC patients who will never receive a second-line treatment, the rationale of this strategy is to maximize treatment outcome within the first-line setting. Methods: We performed an in vivo study using human BRAF V600E CRC cell line-derived xenografts in nude mice. We evaluated the efficacy of encorafenib (E) + cetuximab (C), FOLFOX, and FOLFIRI, both as individual regimens and in combinations. Mice were treated for 3 weeks and followed for an additional 8 weeks to evaluate durability of tumor control. Additionally, we validated our findings using 3 BRAF V600E mutated patient derived xenografts. Tumors progressing on single agent and combined treatment were profiled by RNA sequencing, protein extraction for RPPA/Western blot, and establishment of in vitro primary cell cultures for further analyses. Results: Our study showed across all 4 models both FOLFOX and FOLFIRI, each in combination with encorafenib plus cetuximab, having greater efficacy than encorafenib plus cetuximab or either chemotherapy alone. No significant change in toxicity was seen with the addition of chemotherapy. Interestingly, in the one model with long term treatment, FOLFOX + E +/- C performed greatest over the long-term, with significant endpoint separation against all other treatment arms (P &lt; 0.05). Conclusions: Taken together, results from our study suggest that the addition of chemotherapy to BRAF+EGFR targeted therapy can further increase the magnitude of response in BRAF V600E mCRC and is a promising combination now being explored clinically. Additionally, this research will substantially contribute to our understanding of the genetic and molecular bases of resistance to target therapies and chemo-based approach in BRAF V600E context.
Handbuch der Ernährungslehre.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal